Kornimate/medical-research-clean huggingface dataset:
modified "open intraperitoneal mesh" technique of incisional ventral hernia repair

Conditions: Incisional Ventral Hernia; Recurrent Ventral Hernia

Summary: ventral hernias, primary and recurrent, are major surgical challenge. we aim to investigate efficacy of modified technique of ventral hernias repair: an "open intraperitoneal mesh" technique.

we analyzed early postoperative complications (epcs; wound infection, hematoma, and seroma) and late postoperative complications (recurrence) in 124 patients operated for ihs and recurrent ihs (rihs) using our new technique. our technique involved repairing hernias by preserving the hernia sac, which was later used to conceal the mesh that replaced the abdominal wall defect, thus dividing the mesh from subcutaneous tissue.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older * american society of anesthesiologists physical status i, ii, iii exclusion criteria: * refusal of the patients to give informed consent

Keywords: ventral hernia infection hematoma seroma recurrence mesh technique
westlake n-of-1 trials for macronutrient intake

Conditions: Postprandial Hyperglycemia; Metabolic Disorder, Glucose

Summary: this is a dietary intervention study in students and staff of westlake university, which is designed to provide evidence in support of n-of-1 methods as an approach to advance personalized nutrition. the primary aim is using a series of n-of-1 trials to determine the impacts of a high fat, low carbohydrate diet (hf-lc) on glucose metabolism and gut microbiota in subjects versus a low fat, high carbohydrate diet (lf-hc) at both the individual and group level.

this study will employ a series of individual n-of-1 trials comparing a high fat, low carbohydrate diet (hf-lc) to a low fat, high carbohydrate diet (lf-hc). participants will enter the study on a usual diet and will have a 6-day run in period for diet planning and baseline data collection before beginning their intervention. the hf-lc or the lf-hc will be randomized as the starting intervention followed by a wash-out period lasting for 6 days with normal diet between two interventions to eliminate previous intervention effects. then the participants will be provided with the other diet. both hf-lc and lf-hc last for 6 days in each set which consists of two wash-out periods and two intervention periods. there will be 3 sets in this study and investigators will aggregate the results of the completed n-of-1 trials across all participants to estimate the group level impacts of hf-lc compared to lf-hc.

Eligibility criteria:
inclusion criteria: * willingness and capability to complete the study protocol exclusion criteria: * inability or unwillingness to approved to provide informed consent * neurological conditions that might affect the assessment of the study measurement * hospitalization or surgery planned within 3 months * gastrointestinal diseases * other serious medical conditions, such as liver, kidney, or systemic disease * women who are pregnant or lactating * tobacco, alcohol, or illicit drug abuse * had taken antibiotics in the past two weeks prior to the start of the trial * participants on a vegan diet * any food allergy * lack of smart phone and data plan for participating caregiver * non-chinese speaking participants * participating in another concurrent intervention study

Keywords: personalized nutrition glucose metabolism gut microbiota
study of the determinants of coronary atherosclerosis in familial hypercholesterolemia (athero-fh study)

Conditions: Familial Hypercholesterolemias; Atherosclerotic Cardiovascular Disease (ASCVD)

Summary: the goal of this study (interventional clinical research not involving a health product) is to assess the prevalence of subclinical coronary atherosclerosis diagnosed by coronary ct angiography in heart failure patients in primary prevention, across different levels of cardiovascular risk defined by coronary artery calcium (cac) score percentiles (based on data from the mesa study): low risk (≤25th percentile for age, sex, and ethnicity), intermediate risk (25th \ 75th percentile). the patients will attend an on-site visit at inclusion (and must undergo a coronary ct angiography within 6 months following this visit), will be contacted by phone at 1 year and 2 years, and will return for an on-site visit at 30 months.


Eligibility criteria:
inclusion criteria: * person willing to sign the study consent form * person affiliated with a current social security scheme * person with a definite diagnosis of familial hypercholesterolemia, defined by a dutch lipid clinic network (dlcn) clinical-biological score \> 8 and/or an identified causal mutation in the ldl receptor (ldlr) gene, apolipoprotein b100 gene, pcsk9 gene, or apolipoprotein e gene * male aged 40 years or older, or female aged 50 years or older * ability to understand french for questionnaire completion * person not taking any lipid-lowering medication or on a stable dose of lipid-lowering therapy for at least one month prior to inclusion (three months for pcsk9 inhibitors) at visit 1 * person not taking any antihypertensive medication or on a stable dose of antihypertensive therapy for at least one month at visit 1 * person not taking any antidiabetic medication or on a stable dose of antidiabetic therapy for at least 3 months at visit 1 exclusion criteria: * subject with a technical contraindication for coronary ct scan: patient diameter \> 70 cm and/or weight \> 250 kg * patient with a history of atherosclerotic cardiovascular event (myocardial infarction, ischemic heart disease, coronary revascularization, ischemic stroke, carotid endarterectomy, lower limb arterial revascularization) * patient allergic to iodinated contrast agents * severe renal insufficiency: estimated glomerular filtration rate (egfr) according to the ckd-epi formula ≤ 30 ml/min * subject with active cancer or in remission for less than 3 years * subject who has received oral or intravenous corticosteroid therapy within the last 6 months * subject with untreated or poorly controlled hypothyroidism * subject receiving immunosuppressive or anticancer therapy * subject refusing to participate * subject under guardianship, curatorship, or judicial protection, or without social insurance coverage * pregnant woman

Keywords: familial hypercholesterolemia atherosclerotic cardiovascular disease
obesity surgery and kidney transplant for patients with obesity and renal failure

Conditions: Severe Obesity; Renal Failure

Summary: gastric bypass followed by renal transplantation is superior to medical management followed by renal transplant for patients with severe obesity and renal failure.


Eligibility criteria:
inclusion criteria: * body mass index 40-55 kg/m2 * age less than 60 years * available support person * adequate insurance * all other criteria required for renal transplantation exclusion criteria: * schizophrenia * bipolar disorder * crohn's disease * human immunodeficiency virus * cirrhosis * prior weight loss surgery * prior mesh hernia repair * prior anti-reflux surgery * inability to walk 200 feet * significant coronary disease * significant lung disease - fixed expiratory volume 1 less than 75% or on oxygen * addiction to alcohol or drugs * inability to quit smoking * jehovah's witness * non-compliance with dialysis regimen * previous renal transplant * non-english speaking

Keywords: obesity renal failure gastric bypass
pharmacokinetics of baf312 in patients with hepatic impairment

Conditions: Hepatic Impairment

Summary: this study will investigate the pharmacokinetics of baf312 in patients with mild, moderate and severe hepatic impairment compared to healthy control subjects.


Eligibility criteria:
inclusion criteria: all subjects: * male and female caucasian subjects 18 to 70 years of age * at least 50 kg and body mass index (bmi) within 18-35 kg/m2. * cyp2c9 wild-type (cyp2c9\*1 homozygous carriers) hepatic impairment: - subjects must have either mild, moderate or severe hepatic impairment exclusion criteria: all subjects * hepatic impairment due to non-liver disease. * use of other investigational drugs within certain timelines * donation or loss of 400 ml or more of blood or plasma within eight (8) weeks prior to initial dosing * history of cardiac rhythm abnormalities or cardiac rhythm abnormalities identified in the 24-h holter ecg recording including episodes of bradycardia (hr \ 100/24h, or higher grade), or supraventricular arrhythmias (other than occasional supraventricular ectopic beats with a maximum of 5 subsequent ectopic beats per event) or subjects with conduction disturbances (higher than av-block grade 1) or bradycardia or tachycardia. * history of cardiac catheter ablation. * women of child-bearing potential * history of malignancy of any organ system * recent and/or recurrent history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease) * history or presence of symptomatic postural hypotension or syncope. * total wbc or lymphocyte counts which falls outside the 1.5-fold local laboratory normal range or platelet count \< 30,000/μl at screening or baseline. * clinically significant infection or recent vaccination with live-attenuated vaccines. * history or presence of hepatitis b or c and/or positive hepatitis b surface antigen (hbsag) or hepatitis c test result at screening. * history or presence of coronary heart disease (stable or unstable), myocardial infarction, myocarditis, cardiomyopathy, heart failure nyha ii - iv. hepatic impairment: * history or presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk. * any surgical or medical condition other than hepatic impairment which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the study subject in case of participation in the study. * treatment with certain drugs healthy subjects: * history or presence of any clinically significant disease of any major system organ class including (but not limited to) cardiovascular, metabolic, renal, neurological or psychiatric diseases. * any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, drugs, or which may jeopardize the subject in case of participation in the study.

Keywords: baf312 pharmacokinetics hepatic impairment
uwccc molecular tumor board registry

Conditions: Hematologic Neoplasms; Solid Neoplasm

Summary: this study seeks to evaluate the clinical utility of the precision medicine molecular tumor board, and to track patient outcomes.


Eligibility criteria:
inclusion criteria: * clinically suspected or histologically confirmed solid or hematological malignancy * undergoing genetic testing of tumor * ability to understand written informed consent document * willingness to sign written informed consent document exclusion criteria: * pediatric patients (age\<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
contrast sonography for evaluation of liver tumors prior to radiofrequency ablation

Conditions: Liver Neoplasms

Summary: the purpose of this study is to determine the efficacy of the definity (perflutren lipid microsphere injectable suspension) ultrasound contrast agent in identifying small tumors (hepatomas \& metastases) within the liver. primary objective: to estimate the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography secondary objectives: to estimate the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography

an estimated 75 patients (age 18 years of age or older) will be enrolled from the population of patients who present for ultrasound-guided radiofrequency ablation (rfa) of ct or mri-confirmed multiple primary hepatocellular carcinoma (hcc) or metastatic carcinoma, with at least one of the tumors being ≤ 1.5 cm in diameter.

Eligibility criteria:
inclusion criteria: * patients with primary hepatocellular carcinoma (hcc) or secondary (metastatic) carcinoma of the liver who have been referred for ultrasound-guided radiofrequency ablation (rfa) treatment * recent (within 90 days) ct or mri scan with report of one or more tumors ≤ 1.5 cm in diameter * patient is stable and is to be managed conservatively (i.e. non-surgically) * 18 years of age or older * ability and willingness to provide written informed consent exclusion criteria: * known or suspected cardiac shunt(s) * known sensitivity to octafluoropropane * pregnant or breastfeeding

Keywords: liver cancer
efficacy of methylene blue for malaria treatment in adults of burkina faso: proof of principle study in semi-immune adults of burkina faso in the frame of the a8 project of the sfb 544

Conditions: Malaria

Summary: design: single-centre, controlled study in adults with uncomplicated falciparum malaria in the nouna health district, north-western burkina faso phase: phase ii objectives: the primary objective of this trial is to study the efficacy of different methylene blue regimens given to adults with uncomplicated falciparum malaria in an african area of high malaria transmission intensity. population: male adults with uncomplicated malaria from nouna town. sample size: n= 60 (n=20 for each group; three different dosing regimens of mb). treatment: the participants in the three different mb regimens will receive orally twice daily 390 mg mb (total daily dose 780mg) over 7,5 or 3 days respectively. treatment with the five (three) day regimen will only start after all patients of the seven (five) days regimen have been followed up until day 3. endpoints: the primary endpoint is the adequate clinical and parasitological response (acpr) rate on day 28. secondary endpoints are the number of adverse events (ae) after drug intake until day 28, clinical and parasitological failure rates on day 14 and 28, changes in haemoglobin/haematocrit until day 28, and fever and parasite clearance time.


Eligibility criteria:
inclusion criteria: * male adults (\>17 years;\<55 years) * uncomplicated malaria caused by p. falciparum * asexual parasites ≥ 1000/µl and ≤ 200 000/µl * axillary temperatures ≥ 37.5°c or history of fever during 48 hours * living in nouna health district * informed consent exclusion criteria: * complicated or severe malaria * any apparent significant disease * anaemia (haematocrit \< 21%) * antimalarial treatment prior to inclusion (last three days) * increased creatinine blood levels
a study of ozanimod in pregnant women with ulcerative colitis and their offspring

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to evaluate association between ozanimod exposure during pregnancy and subsequent maternal, fetal, and infant outcomes.


Eligibility criteria:
inclusion criteria: * currently or recently pregnant * diagnosis of uc * resident of country where ozanimod is prescribed for the treatment of uc exclusion criteria: * exposure to other s1p therapies at any time during pregnancy other protocol-defined eligibility criteria apply.

Keywords: zeposia® ozanimod pregnancy sphingosine-1-phosphate (s1p) therapies inflammatory bowel disease ibd ulcerative colitis uc
ngs mrd-guided blinatumomab treatment for pediatric b-all

Conditions: B Cell Precursor Acute Lymphoblastic Leukemia; Pediatric; Minimal Residual Disease; Next Generation Sequencing (NGS)

Summary: the goal of this clinical trial is to determine whether pediatric b-cell acute lymphoblastic leukemia (b-all) patients with negative deep minimal residue disease (mrd) can benefit from blinatumomab treatment. the main questions it aims to answer are: 1. whether the application of blinatumomab can improve the long-term survival of next generation sequence (ngs) mrd-positive b-all children after consolidation therapy? 2. whether the application of blinatumomab can benefit the ngs mrd-negative b-all children after consolidation therapy?


Eligibility criteria:
inclusion criteria: * clincial dianogsis of acute lymphoblastic leukemia (b-cell type) by morphology, immunology, cytogenetics, and molecular biology (micm). * age ≥1 year and \<18 years. * informed consent signed, with the parents or guardians agreeing to a unified treatment protocol. exclusion criteria: * age \<1 year or ≥18 years. * immunophenotyping suggests mature b-cell leukemia, mixed-lineage leukemia, or t-cell acute lymphoblastic leukemia. * secondary leukemia or second tumor, cml blast phase all. * other tumors or immunodeficiency diseases present.
danish cardiogenic shock trial

Conditions: Cardiogenic Shock Acute; Acute Myocardial Infarction

Summary: cardiogenic shock a serious complication of a heart attack (myocardial infarction). despite rapid invasive treatment, circulatory support using positive inotropes and mechanical support with intra-aortic balloon counterpulsation (iabp), and evaluation of several new treatments during the last decade, the mortality in patients with cardiogenic shock still exceeds 50%. an alternative to current management is restoration of the volume of blood pumped by the heart (cardiac output) using a ventricular assist device. in the acute setting this is difficult but can be done using the impella device which is a catheter-based, axial flow pump that pumps blood directly from the left ventricle into the circulation thereby restoring blood flow to the failing organs. in 2012 a more powerful impella has been introduced that is able to deliver 3.5l/min (approximately 75% of a normal cardiac output). the hypothesis of the current study is to reduce mortality and morbidity of patients with cardiogenic shock using the impella cp. the study will be carried out as a randomized multicenter study where eligible patients will be randomized to receive conventional circulatory support or support with the impella device and inotropic support if needed. a total of 360 patients are planned to be enrolled, and the primary endpoint will be death.


Eligibility criteria:
inclusion criteria: 1. st segment elevation myocardial infarction of less than 36 hours' duration, confirmed by new onset st-segment elevation, or emergency angiography demonstrating acute occlusion of coronary artery, and 2. cardiogenic shock of less than 24 hours' duration, confirmed by: * peripheral signs of tissue hypoperfusion (arterial blood lactate ≥2.5mmol/l and/or svo2 \<55% with a normal pao2) and * systolic blood pressure less than 100mmhg and/or need for vasopressor therapy (dopamine/ norepinephrine or epinephrine), and 3. left ventricular ejection fraction of less than 45% visually estimated or by wall motion score index \>1,6. exclusion criteria: 1. other causes of shock (hypovolemia, hemorrhage, sepsis, pulmonary embolism or anaphylaxis). 2. shock due to mechanical complication to myocardial infarction (papillary muscle rupture, rupture of the ventricular septum or rupture of free wall). 3. severe aorta valve regurgitation/stenosis. 4. predominant right ventricular failure. 5. out of hospital cardiac arrest with persistent glasgow coma scale \<8 after return of spontaneous circulation. 6. shock duration\>24 hours. 7. known heparin intolerance. 8. already established mechanical circulatory support 9. do not resuscitate wish.
study of circulating and tumor biomarkers in breast cancer patients

Conditions: Breast Cancer

Summary: aims: to evaluate the role of monoclonal antibodies in the detection of cancer specific antigens in blood and tumor tissue, and the potential use of these antibodies for future evaluation for therapy. also, to evaluate the presence of circulating tumor cells (ctcs) and to study emt (epithelial-mesenchymal) signature changes during chemotherapy. methods: to take 20mls of blood from advanced breast cancer patients before a new course of anti-cancer therapy, and another 20mls of blood 3 weeks after treatment. in addition, consent will be obtained to cut 10-15 tissue sections from their archival tumor specimens. whenever possible, the blood taking will be timed such that no additional needle prick will be done specifically for the purpose of the study, by coinciding it with standard blood taking which is required for the patient's treatment. importance of proposed research to science or medicine:detection of tumor specific antigens in the blood may potentially reduce the need for more invasive biopsies for confirmation of diagnosis of cancer or follow-up of cancer in the future. the identification and development of antibodies specific to these tumor antigens or markers may offer future therapeutic options, or as a vehicle to deliver cytotoxic therapy. identification of ctcs as well as understanding the changes that occur in emt signature in these circulating tumor cells may serve as a means of potential means of prognostication and modification of therapy in the future. potential benefits and risks: potential risks to the patient include that of blood taking (pain, feeling faint, infection). patients will not benefit directly from the study but the knowledge gained may help the management of future patients. cancer biomarkers, such as antigens and circulating tumor cells, may be a potential area to developing new methods of diagnosis and treatment of cancer. monoclonal antibiotics are now able to be identified and isolated that may specifically target progenitors of breast cancer as well as ctcs. the changes that occur to ctcs during treatment may serve as a means of prognostication, as well as allow for therapeutic modifications. clinical correlative studies into these areas (mabs and ctcs) will serve to determine the role of these in clinical application in the future.


Eligibility criteria:
inclusion criteria: * advanced breast cancer patients whose cancer have progressed and are due to start a new course of anti-cancer therapy.the patient needs to have had previous breast cancer surgery at nuh (lumpectomy or mastectomy) or a diagnostic core biopsy for breast cancer, and consent to allow for blood taking and access to archival tissue. exclusion criteria: * no available archival tumor specimen at nuh.
tacs improves memory in elders with subjective memory complaints

Conditions: Memory Deficits; tACS

Summary: subjective memory complaints (smc), the main cognitive component of which is event memory, is a predictor of alzheimer's disease in elderly people. the purpose of this study was to investigate the effect of transcranial alternating current stimulation (tacs) with theta frequency (6 hz) on the medial prefrontal cortex in the improvement of episodic memory in individuals with smc in a double blind, randomized, and sham-controlled parallel study. sixteen participants with smc received either active or sham theta tacs on the medial prefrontal cortex (mpfc). eeg was recorded and rey auditory verbal learning test (ravlt) was administered. the aim of the current study was to see if theta tacs over the mpfc can improve event memory in individuals with smc and thus can be considered a potential therapeutic intervention for this population or not.


Eligibility criteria:
inclusion criteria: * being 50 or older, * mini mental state examination (mmse) grade from 27 to 30 * total score of 58 or more on the everyday memory questionnaire (emq) * no indications of depression and anxiety measured by geriatric depression scale (gds) and state-trait anxiety inventory (stai) * no sign of dementia based on diagnostic and statistical manual of mental disorder, 5th edition (dsm-v) criteria exclusion criteria: * history of a major psychological or neurological condition * history of head trauma leading to unconsciousness, * presence of metal in the head * history of seizures * serious cardiovascular disease * use of medications with an impact on cognitive functions * recent use of alcohol or substance abuse

Keywords: episodic memory medial prefrontal cortex tacs smc